The conformational basis of thrombosis

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 14-22

  Carrell, R W ^a   Huntington, J A ^a   Mushunje, A ^a   Zhou, A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alzheimer's disease; Antithrombin; Conformational change; Latent antithrombin; Prions

Indexed keywords

ANTITHROMBIN;

ALZHEIMER DISEASE; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; DEMENTIA; DIMERIZATION; ELECTROPHORETIC MOBILITY; FEVER; HIGH TEMPERATURE; HUMAN; INFECTION; LATENT PERIOD; PASTEURIZATION; PLASMA; PRION DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN VARIANT; STRUCTURE ANALYSIS; THROMBOEMBOLISM; THROMBOSIS;

EID: 0034912329     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616196     Document Type: Conference Paper

References (40)

1. Prion diseases and the BSE crisis
2. Conformational diseases
3. Conformational changes and disease - Including Serpins, Prions and Alzheimer's
4. The serpin family of proteinase inhibitors: Structure function and regulation
5. Structure of a serpin-protease complex shows inhibition by deformation
6. 1-globulin pattern of serum in α1-antitrypsin deficiency
7. Molecular mechanism of Z α1-antitrypsin accumulation in the liver
8. Familial dementia caused by polymerisation of mutant neuroserpin
9. 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function
10. 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis
11. Mobile reactive centre of serpins and the control of thrombosis
12. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants
13. 1-antitrypsin
14. 1-antichymotrypsin in chronic bronchitis and emphysema
15. Structural basis of latency in plasminogen activator inhibitor-1
16. The anticoagulant activation of antithrombin by heparin
17. Implications for function and therapy of a 2.9Å structure of binary-complexed antithrombin
18. A 2.6Å structure of a serpin polymer and implications for conformational disease
19. Mobile reactive centre of serpins and the control of thrombosis
20. Preparative induction and characterization of L-antithrombin: A structural homologue of latent plasminogen activator inhibitor-1
21. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen VI (187 Asn→Asp)
22. Commercial antithrombin concentrate contains inactive L-forms of antithrombin
23. Crystallization and preliminary X-ray diffraction analysis of two conformations of intact human antithrombin
24. Biological implications of a 3Å structure of dimeric antithrombin
25. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions
26. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
27. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells
28. Formation of the antithrombin heterodimer and the onset of thrombosis
29. Heteropolymerization of S, I, and Z alpha1 antitrypsin and liver cirrhosis
30. What do dysfunctional serpins tell us about molecular mobility and disease?
31. A phenylalanine 402 to leucine mutation is responsible for a stable inactive conformation of antithrombin
32. Antithrombins Wibble and Wobble (T85M/K): Archetypal conformational disease with in vivo latent-transition, thrombosis and heparin activation
33. Antithrombin mutation database: 2nd (1997) update. For the plasma coagulation inhibitors subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
34. Isolation and characterisation of an antithrombin III variant with reduced carbohydrate content and enhanced affinity for heparin
35. The oligosaccharide sidechain on Asn-135 of α-antithrombin, absent in β-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change
36. Thrombin inhibition by antithrombin on the subendothelium is explained by the isoform ATβ
37. New conformational mutation PRO80SER in the antithrombin III. Clinical effect in an extended family including 13 carriers
38. Molecular characterization of the first homozygous heparin cofactor II deficiency. Involvement in conformational disease
39. The molecular basis of antithrombin deficiency in Belgian and Dutch families
40. Micromethod identifies latent antithrombin in normal plasma and shows pleiotropic changes are due to conformational instability